Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2023
In the second week of life, 83 percent of newborns who were fed formula milk had Clostridium difficile and Clostridium perfringens, but by the end of the third week, all infants had these infections.
Read Full NewsMind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]
The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.
1.
Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit
2.
La interacción GBP3-STING en el glioblastoma coordina la respuesta deficiente al temozolomide.
3.
SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control
4.
Breast Cancer Genetic Testing Need in Black Women Identified
5.
Preoperative Embolization Linked to Relapse-Free Survival in Meningioma
1.
ctDNA in Aggressive B-Cell Lymphoma: Redefining MRD and Prognostic Monitoring
2.
Pediatric Cancer Cell Line Authentication and Reproducibility
3.
Surgical Innovation Using Hematopoietic Reserve Preservation During Major Surgery
4.
3D Genome Reorganization in Cancer Cells: Mechanisms, Clinical Implications, and Emerging Therapeutic Frontiers
5.
Cancer Immunotherapy: Advances, Guidelines, and Practical Tools for Modern Oncology Practice
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
2.
Thromboprophylaxis In Medical Settings
3.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III
5.
Predicting Delayed Hemolytic Transfusion Reactions Through Donor-Recipient Antigen Exposure Modeling
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge